Drug Profile

Research programme: neurodegenerative disease therapeutics - Amyl Therapeutics

Latest Information Update: 30 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amyl Therapeutics
Class Antibodies; Antidementias; Antiparkinsonians
Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Tau protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

07 Nov 2023 Amyl Therapeutics plans a proof-of-concept phase I trial for Amyloidosis in mid 2024
04 Oct 2022 Preclinical trials in Alzheimer's disease in Belgium (Parenteral) before October 2022 (Amyl Therapeutics pipeline, October 2022)
04 Oct 2022 Preclinical trials in Parkinson's disease in Belgium (Parenteral) before October 2022 (Amyl Therapeutics pipeline, October 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com